Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998813 | 0.95 | MAPK14 (0.34) | MAPK14TNFCDK8MAPK13MAPK12 | |
| SCHEMBL5989027 | 0.95 | MAPK14 (0.33) | MAPK14TNFCDK8MAPK13MAPK12 | |
| SCHEMBL5988417 | 0.91 | MAPK14 (0.34) | MAPK14TNFCDK8MAPK13MAPK12 | |
| SCHEMBL5987486 | 0.90 | TNF (0.34) | MAPK14TNFCDK8 | |
| SCHEMBL5987723 | 0.84 | MAPK14 (0.36) | MAPK14TNFCDK8MAPK13MAPK12 | |
| SCHEMBL5988889 | 0.84 | TNF (0.33) | MAPK14TNF | |
| SCHEMBL4081556 | 0.83 | MAPK14 (0.53) | MAPK14TNFCDK8MAPK13MAPK12 | |
| SCHEMBL6270455 | 0.83 | MAPK14 (0.36) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL4092259 | 0.79 | MAPK14 (0.51) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL5991513 | 0.79 | TNF (0.35) | MAPK14TNFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545514-A1 | ANTICOAGULANT AND FIBRINOLYTIC THERAPY USING P38 MAP KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-06-29 | — | — | EP | disclosed |
| EP-1530477-A1 | COMBINATION THERAPY WITH p38 MAP KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-05-18 | — | — | EP | disclosed |
| EP-1427412-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-06-16 | — | — | EP | disclosed |
| WO-2004016267-A1 | ANTICOAGULANT AND FIBRINOLYTIC THERAPY USING P38 MAP KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004014387-A1 | COMBINATION THERAPY WITH p38 MAP KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2003022273-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |